Brief: Xvivo Perfusion Q3 EBITDA Grows To SEK 5.9 Mln
Oct 27 (Reuters) - Xvivo Perfusion AB XVIVO.ST :
* INTERIM REPORT JANUARY - SEPTEMBER 2022
* Q3 NET SALES AMOUNTED TO SEK 96.8 MILLION (54.9)
* Q3 EBITDA AMOUNTED TO SEK 5.9 MILLION (4.2)
* Q3 OPERATING INCOME (EBIT) AMOUNTED TO SEK -4.7 MILLION
(-4.0)
Source text for Eikon: ID:nMFN54JdjZ
Further company coverage: XVIVO.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Xvivo Perfusion AB
See all newsSweden's XVIVO Q3 revenue beat expectations on thoracic sales
Brief: Xvivo Q3 EBIT SEK 28 Million
Brief: Xvivo Receives CE Certificates For Heart Preservation Technology
Brief: XVIVO Gets FDA Approval For Additional Patient Enrollment
Sweden's XVIVO Q2 sales beat estimates, helped by thoracic segment strength